.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Baxter
Fish and Richardson
Chinese Patent Office
AstraZeneca
US Army
Johnson and Johnson
Queensland Health
Fuji
Cantor Fitzgerald

Generated: November 21, 2017

DrugPatentWatch Database Preview

LUMIGAN Drug Profile

« Back to Dashboard

What is the patent landscape for Lumigan, and when can generic versions of Lumigan launch?

Lumigan is a drug marketed by Allergan and is included in two NDAs. There are twelve patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-three patent family members in twenty-one countries and three supplementary protection certificates in three countries.

The generic ingredient in LUMIGAN is bimatoprost. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

Summary for LUMIGAN

Pharmacology for LUMIGAN

Ingredient-typeProstaglandins
Drug ClassProstaglandin Analog

Medical Subject Heading (MeSH) Categories for LUMIGAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC021275-001Mar 16, 2001DISCNYesNo► Subscribe► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► Subscribe ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LUMIGAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC021275-001Mar 16, 2001► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC022184-001Aug 31, 2010► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC021275-001Mar 16, 2001► Subscribe► Subscribe
Allergan
LUMIGAN
bimatoprost
SOLUTION/DROPS;OPHTHALMIC021275-001Mar 16, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for LUMIGAN

Drugname Dosage Strength RLD Submissiondate
bimatoprostOphthalmic Solution0.01%Lumigan4/5/2011
bimatoprostOphthalmic Solution0.03%Lumigan12/22/2008

International Patent Family for Tradename: LUMIGAN

Country Document Number Estimated Expiration
Japan2011148827► Subscribe
Norway337190► Subscribe
Russian Federation2363471► Subscribe
Argentina055050► Subscribe
New Zealand560788► Subscribe
China101137383► Subscribe
Hong Kong1104211► Subscribe
Mexico2007011300► Subscribe
Japan5899267► Subscribe
BrazilPI0607447► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LUMIGAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB02/035United Kingdom► SubscribePRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
C0033France► SubscribePRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
00099Netherlands► SubscribePRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Boehringer Ingelheim
Colorcon
Daiichi Sankyo
Covington
Cerilliant
Novartis
Farmers Insurance
Medtronic
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot